Breaking News Instant updates and real-time market news.

Q

QuintilesIMS

$80.02

0.14 (0.18%)

, BMY

Bristol-Myers

$56.73

-0.03 (-0.05%)

08:03
11/22/16
11/22
08:03
11/22/16
08:03

Quintiles forms new collaboration with Bristol-Myers, Lilly Merck KGaA, Pfizer

QuintilesIMS (Q) announced that it will lead a collaborative initiative involving founding partners Bristol-Myers Squibb (BMY), Eli Lilly (LLY), Merck KGaA (MKGAY), and Pfizer (PFE), which aims to provide clearer and more proactive insight into how anti-cancer treatments are used in a real-world setting across key European markets. "Additional information about how oncology products are actually used, for which types of patients, with what sequences and combinations of therapies, and in which indications, is particularly important to help improve oncology patient care. This new initiative is intended to provide more timely, consistent and comprehensive data resources that could be used to provide further insight for healthcare systems to make better informed decisions on patient care in the future. Importantly, substantial steps have been taken to obtain these insights while respecting individual privacy," the company said.

Q

QuintilesIMS

$80.02

0.14 (0.18%)

BMY

Bristol-Myers

$56.73

-0.03 (-0.05%)

LLY

Eli Lilly

$76.64

-0.03 (-0.04%)

MKGAY

Merck KGaA

$33.37

-0.22 (-0.65%)

PFE

Pfizer

$31.57

0.09 (0.29%)

  • 03

    Dec

  • 04

    Dec

Q QuintilesIMS
$80.02

0.14 (0.18%)

10/05/16
GSCO
10/05/16
INITIATION
Target $94
GSCO
Buy
Quintiles initiated with a Buy at Goldman
Goldman analyst Robert Jones removed his Not Rated designation and added Quintiles to the Buy list with a $94 price target. Jones thinks the strong CRO industry backdrop, modest improvements in win and conversion rates will result in upside to estimates/guidance.
10/05/16
UBSW
10/05/16
NO CHANGE
Target $90
UBSW
Buy
Quintiles price target raised to $90 from $78 at UBS
UBS analyst Jonathan Groberg raised his price target on Quintiles to $90 from $78 following the completion of its merger with IMS Health. The analyst is positive on the stock citing its significant scale in a consolidating industry and near-term strength in its business. Groberg reiterated his Buy rating on Quintiles shares.
10/19/16
JEFF
10/19/16
DOWNGRADE
Target $79
JEFF
Hold
Quintiles downgraded to Hold from Buy at Jefferies
Jefferies analyst David Windley downgraded Quintiles (Q) to Hold citing concern over the revenue synergy targets from the IMS merger. Windley notes that his firm's survey work indicates sponsors remain skeptical of IMS data's value in speeding clinical trial execution. He lowered his price target for the shares to $79 from $80. The analyst's top picks in Pharmaceutical Services are Charles River (CRL), INC Research (INCR) and PRA Health (PRAH).
10/27/16
PIPR
10/27/16
DOWNGRADE
Target $72
PIPR
Neutral
Quintiles downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Sean Wieland downgraded Quintiles to Neutral saying risks from the merger with IMS are not priced in. Consolidation of data suppliers may increase data acquisition costs in 2018, Wieland tells investors in a research note. Further, he believes the business of clinical trial recruitment will get more challenging. The analyst lowered his price target for Quintiles to $72 from $75.
BMY Bristol-Myers
$56.73

-0.03 (-0.05%)

10/28/16
10/28/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Twitter (TWTR) upgraded to Perform from Underperform at Oppenheimer with analyst Jason Helfstein saying the stock's valuation now "properly" reflects the challenging fundamental outlook. 2. Bristol-Myers (BMY) upgraded to Long-Term Buy from Neutral at Hilliard Lyons. 3. Qualcomm (QCOM) upgraded on valuation at BMO Capital with analyst Tim Long saying he is neutral on Qualcomm's acquisition of NXP (NXPI), but he expects Qualcomm's stock to stay in a trading range in the wake of the deal. 4. Level 3 (LVTL) upgraded to Outperform from Perform at Oppenheimer with analyst Timothy Horan saying the company has restructured itself in the last few years and now has operational/financial flexibility on free cash flow, with the analyst seeing accelerating growth in 2017. 5. ConocoPhillips (COP) upgraded to Overweight from Neutral at Piper Jaffray with analyst Guy Baber saying the company reported "another solid quarter." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/28/16
HDLY
10/28/16
UPGRADE
HDLY
Long-Term Buy
Bristol-Myers upgraded to Long-Term Buy from Neutral at Hilliard Lyons
11/03/16
JPMS
11/03/16
NO CHANGE
JPMS
JPMorgan calls Lilly, Bristol-Myers, Allergan favorite pharma majors
Following a "challenging" Q3 earnings season for the major pharmaceuticals companies, JPMorgan analyst Chris Schott said pricing continues to be a major overhang on the space. However, he believes these and other challenges are "increasingly well reflected" in both earnings and sector multiples and recommends companies early in new product launch cycles. Coming out of the earnings season, Schott named Eli Lilly (LLY), Bristol-Myers (BMY) and Allergan (AGN) as his favorite names in the large-cap pharma space.
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
LLY Eli Lilly
$76.64

-0.03 (-0.04%)

11/03/16
BMOC
11/03/16
NO CHANGE
BMOC
Eli Lilly factored pricing pressure into guidance, says BMO Capital
After meeting with Eli Lilly, BMO Capital analyst Alex Arfaei reports that the company seemed surprised at the intensity of investors' concerns about pricing pressure on it. The analyst says that the company anticipated pricing pressure and factored it into its guidance. The analyst keeps a $91 price target and an Outperform rating on the shares.
11/11/16
JEFF
11/11/16
NO CHANGE
Target $100
JEFF
Buy
Jefferies bullish on Lilly regardless of Alzheimer's data
Jefferies analyst Jeffrey Holford believes shares of Eli Lilly "can work over time" regardless of Alzheimer's disease drug solanezumab's Phase III study outcome. The analyst, however, says he has enough confidence to recommend Lilly shares ahead of the EXPEDITION3 data readout. Holford increased his base case solanezumab peak sales to $5B. He says Lilly remains one of his top picks with a Buy rating and $100 price target.
11/15/16
JPMS
11/15/16
NO CHANGE
Target $95
JPMS
Overweight
JPMorgan sees favorable risk/reward for Lilly into Alzheimer's data
JPMorgan analyst Chris Schott sees a favorable risk/reward profile for shares of Eli Lilly into the solanezumab data for Alzheimer's, which is expected by year-end. Favorable data from the EXPEDITION-3 trial would represent a catalyst not just for Lilly and other Alzheimer's associated names but for the biopharma space as a whole, Schott tells investors in a research note. The analyst expects 20%-plus share upside in the event the trial is successful on both primary and secondary endpoints. He assigns a 10%-20% probability to this outcome. Schott sees 10%-20% share upside for Lilly should the study hit on its primary but only shows a trend on secondary endpoints. He assigns a 50%-60% probability for this outcome. The analyst also sees a 10% move to the downside if the study fails both endpoints, an outcome he assigns a 20% probability. Schott reiterates an Overweight rating on Lilly with a $95 price target. He believes Lilly's "diverse range of pipeline opportunities" largely supports the valuation at current levels.
MKGAY Merck KGaA
$33.37

-0.22 (-0.65%)

08/12/16
BREN
08/12/16
DOWNGRADE
BREN
Hold
Merck KGaA downgraded to Hold from Buy at Berenberg
PFE Pfizer
$31.57

0.09 (0.29%)

11/02/16
LEER
11/02/16
NO CHANGE
LEER
Pfizer boco failure should not spillover to other PCSK9 antibodies, says Leerink
Leerink analyst Geoffrey Porges says that Pfizer's (PFE) announcement that it is discontinuing development of anti-PCSK9 antibody bococizumab is significant and may give investors pause regarding the entire anti-PCSK9 antibody class. However, the analyst notes that composite of views suggests Boco-specific factors led to disappointment and to the program discontinuation. Further, Porges does not believes investors should expect any similar effects in the longer term follow up with Amgen's (AMGN) Repatha or Regeneron (REGN)/Sanofi's (SNY) Praluent.
11/02/16
11/02/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Hold from Buy at Argus and to Market Perform from Outperform at BMO Capital. 2. BP (BP) downgraded to Hold from Buy at Societe Generale. 3. Corning (GLW) downgraded to Buy from Conviction Buy at Goldman with analyst Doug Clark saying the restocking phase of glass/TV cyclical recovery is now "well understood and largely behind us." 4. Adeptus Health (ADPT) downgraded to Underperform from Buy at BofA/Merrill, to Hold from Buy at Jefferies, and to Equal Weight from Overweight at Stephens. 5. Brookdale Senior Living (BKD) downgraded to Underperform from Neutral at BofA/Merrill, to Market Perform from Outperform at Wells Fargo, and to Outperform from Top Pick at RBC Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/02/16
ARGS
11/02/16
DOWNGRADE
ARGS
Hold
Pfizer downgradedon weaker outlook at Argus
As noted earlier, Argus downgraded Pfizer to Hold from Buy. Analyst Jacob Kilstein cited "recent pipeline setbacks, prospects for increased competition, and management's decision to shelve its business separation plan" as reasons for the downgrade.
11/02/16
BMOC
11/02/16
DOWNGRADE
BMOC
Market Perform
Pfizer downgraded on increased headwinds, uncertainty at BMO Capital
As noted earlier, BMO Capital downgraded Pfizer (PFE) to Market Perform from Outperform. Analyst Alex Arfael says that the company's headwinds, including slowing sales of Ibrance in the U.S. and slower than expected uptake of Prevnar outside the U.S., are intensifying. Additionally, the analyst is less upbeat on Pfizer's IO franchise in the wake of Boco's failure, Target to $33 from $40.

TODAY'S FREE FLY STORIES

11:28
09/22/17
09/22
11:28
09/22/17
11:28
Conference/Events
Wells Fargo financial team holds an analyst/industry conference call »

The Wells Fargo…

DVA

DaVita

$60.84

-0.42 (-0.69%)

11:26
09/22/17
09/22
11:26
09/22/17
11:26
Hot Stocks
DaVita slides after SIRF questions 'massive' leverage to non-profit »

Share of DaVita (DVA) are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIG

Transocean

$9.29

0.21 (2.31%)

11:25
09/22/17
09/22
11:25
09/22/17
11:25
Options
Transocean call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 02

    Oct

11:25
09/22/17
09/22
11:25
09/22/17
11:25
General news
Treasury Action: supply hits next week with $88 B in shorter dated coupons »

Treasury Action: supply…

MSFT

Microsoft

$74.21

-0.73 (-0.97%)

11:25
09/22/17
09/22
11:25
09/22/17
11:25
Conference/Events
Piper Jaffray technology analysts hold an analyst/industry conference call »

Technology Research Team…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 02

    Oct

  • 22

    Oct

DVA

DaVita

$60.94

-0.32 (-0.52%)

11:23
09/22/17
09/22
11:23
09/22/17
11:23
Periodicals
DaVita mentioned cautiously by Southern Investigative Reporting Foundation 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

11:17
09/22/17
09/22
11:17
09/22/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFX

Equifax

$103.15

4.9 (4.99%)

11:16
09/22/17
09/22
11:16
09/22/17
11:16
Hot Stocks
Wells Fargo says time to buy Equifax shares »

Wells Fargo upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

$NYE

NYSE Market Internals

11:16
09/22/17
09/22
11:16
09/22/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAT

Caterpillar

$124.96

0.17 (0.14%)

11:15
09/22/17
09/22
11:15
09/22/17
11:15
Options
Caterpillar put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

CSIQ

Canadian Solar

$15.86

-0.16 (-1.00%)

, JKS

JinkoSolar

$25.83

-0.18 (-0.69%)

11:13
09/22/17
09/22
11:13
09/22/17
11:13
Hot Stocks
Chinese solar names move lower after ITC vote on injury to U.S. producers »

Shares of Canadian Solar…

CSIQ

Canadian Solar

$15.86

-0.16 (-1.00%)

JKS

JinkoSolar

$25.83

-0.18 (-0.69%)

JASO

JA Solar

$7.85

-0.335 (-4.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSLR

First Solar

$48.76

-0.09 (-0.18%)

11:12
09/22/17
09/22
11:12
09/22/17
11:12
Hot Stocks
Breaking Hot Stocks news story on First Solar »

First Solar trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSLR

First Solar

$48.76

-0.09 (-0.18%)

, SPWR

SunPower

$7.37

-0.49 (-6.23%)

11:11
09/22/17
09/22
11:11
09/22/17
11:11
Hot Stocks
First Solar jumps 6%, halted after ITC finds injury to U.S. solar product makers »

SunPower (SPWR) is down…

FSLR

First Solar

$48.76

-0.09 (-0.18%)

SPWR

SunPower

$7.37

-0.49 (-6.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$366.48

-7.43 (-1.99%)

11:09
09/22/17
09/22
11:09
09/22/17
11:09
Hot Stocks
Solar City agrees to pay $29.5M to resolve alleged False Claims Act violations »

The Justice Department…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

FSLR

First Solar

$48.76

-0.09 (-0.18%)

11:08
09/22/17
09/22
11:08
09/22/17
11:08
Hot Stocks
Breaking Hot Stocks news story on First Solar »

First Solar jumps after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSLR

First Solar

11:07
09/22/17
09/22
11:07
09/22/17
11:07
Hot Stocks
Breaking Hot Stocks news story on First Solar »

First Solar trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$49.20

0.71 (1.46%)

11:05
09/22/17
09/22
11:05
09/22/17
11:05
Options
Anadarko call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

AVGO

Broadcom

$240.38

-2.53 (-1.04%)

, SWKS

Skyworks

$102.13

-1.38 (-1.33%)

11:03
09/22/17
09/22
11:03
09/22/17
11:03
Recommendations
Broadcom, Skyworks, Apple analyst commentary  »

Broadcom, Skyworks still…

AVGO

Broadcom

$240.38

-2.53 (-1.04%)

SWKS

Skyworks

$102.13

-1.38 (-1.33%)

AAPL

Apple

$153.39

-2.68 (-1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Oct

  • 22

    Oct

MHK

Mohawk

$245.50

-8.61 (-3.39%)

11:03
09/22/17
09/22
11:03
09/22/17
11:03
Technical Analysis
Technical View: Mohawk slides, analyst action »

The shares were last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NYLD

NRG Yield

$19.20

0.05 (0.26%)

, NRG

NRG Energy

$24.01

-0.18 (-0.74%)

11:02
09/22/17
09/22
11:02
09/22/17
11:02
Hot Stocks
NRG Yield rises after said to be exploring strategic alternatives »

Shares of NRG Yield…

NYLD

NRG Yield

$19.20

0.05 (0.26%)

NRG

NRG Energy

$24.01

-0.18 (-0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

11:00
09/22/17
09/22
11:00
09/22/17
11:00
General news
Treasury Option Action: some call buying at short-end »

Treasury Option Action:…

NYLD

NRG Yield

$19.20

0.05 (0.26%)

10:57
09/22/17
09/22
10:57
09/22/17
10:57
Periodicals
NRG Yield hires banks to explore strategic alternatives, SparkSpread says 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSLR

First Solar

$48.76

-0.09 (-0.18%)

10:55
09/22/17
09/22
10:55
09/22/17
10:55
Options
First Solar put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:50
09/22/17
09/22
10:50
09/22/17
10:50
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

AAL

American Airlines

$46.29

0.87 (1.92%)

, DAL

Delta Air Lines

$48.51

0.35 (0.73%)

10:47
09/22/17
09/22
10:47
09/22/17
10:47
Hot Stocks
Barclays, UBS positive on airlines following recent slide »

Two research firms issued…

AAL

American Airlines

$46.29

0.87 (1.92%)

DAL

Delta Air Lines

$48.51

0.35 (0.73%)

UAL

United Continental

$58.80

0.27 (0.46%)

JBLU

JetBlue

$18.90

-0.35 (-1.82%)

LUV

Southwest

$54.60

-0.03 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.